STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
scientist

BCYC’s Promising Oncology Pipeline: Updates Highlight Strong Efficacy and Tolerability in Key Cancer Trials

byLiliana Vida
September 16, 2024
in Biotechnology, Mid-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

Encouraging Data Supports Advancements in Novel Cancer Therapeutics

BCYC (Bicycle Therapeutics) is continuing to make significant strides in the development of its innovative cancer therapies, with recent updates providing encouraging results for its lead programs. These findings highlight the potential of BCYC’s proprietary Bicycle short peptides as a differentiated approach in the oncology space. This progress is particularly evident in its BT8009 and BT5528 programs, which are at the forefront of BCYC’s efforts to develop targeted cancer treatments.

BT8009: A Promising Candidate in Bladder Cancer

BCYC’s lead candidate, BT8009, has shown promising efficacy and safety in ongoing trials, especially in the treatment of metastatic urothelial carcinoma (mUC), a form of bladder cancer. Updated data from the ongoing trial reveal a 45% objective response rate (ORR) among 38 evaluable patients, with a median duration of response (mDOR) of 11.1 months. This compares favorably to Padcev, an existing treatment for mUC, which demonstrated a 44% ORR and a shorter mDOR of 7.6 months.

One of the standout features of BT8009 is its tolerability profile. While Padcev is associated with challenging side effects such as high-grade skin rash, peripheral neuropathy (PN), and alopecia, BT8009 has a much lower incidence of these side effects, particularly in PN. Notably, no grade ≥3 PN has been observed in patients receiving BT8009. This improved safety profile could position BT8009 as a preferable option for patients, particularly in community settings where managing these side effects can be challenging. Moreover, BT8009’s tolerability could enhance patient quality of life, an area where Padcev has shown limited benefit.

BCYC’s management is optimistic about the ongoing Phase 2/3 Duravelo-2 study for BT8009, which is progressing well with new investigators and sites continuously being added. This additional data and the favorable tolerability profile should aid in the continued enrollment of patients. BCYC may provide further updates on this trial, including an interim analysis on dose selection, in 2025.

BT5528: Efficacy Linked to EphA2 Expression

Another exciting development comes from BCYC’s BT5528 program, which is designed to target EphA2, a protein expressed in several types of cancers, including metastatic urothelial carcinoma (mUC). Updated data suggests a strong correlation between EphA2 expression and patient response. Among 14 mUC patients, those who were EphA2-positive had a 43% ORR, while EphA2-negative patients had a 20% ORR, showcasing the importance of patient selection in improving outcomes.

Additionally, the efficacy of the 6.5mg/m2 dosing regimen administered every two weeks (Q2W) appears more promising than the weekly (QW) regimen, with a 45% ORR observed in the expansion cohort. This suggests that achieving a higher peak concentration (Cmax) of the drug may be more critical to its effectiveness. This dosing regimen will be further evaluated, and BCYC has initiated a combination study of BT5528 with nivolumab (nivo), an immune checkpoint inhibitor, with data expected in 2025. The combination of BT5528 with immunotherapy could present a valuable first-line (1L) treatment opportunity for mUC.

BCYC’s Broader Oncology Pipeline

Beyond BT8009 and BT5528, BCYC is advancing other promising candidates within its Bicycle platform. The company’s platform is centered around the development of Bicycle short peptides, a novel therapeutic modality that combines the advantages of biologics and small molecules. These peptides offer high specificity, rapid tissue penetration, and a unique mechanism of action, making them particularly suited for targeting tumors.

BCYC is developing both Bicycle Toxin Conjugates (BTCs) and Tumor-Targeted Immune Cell Agonists (TICAs) for cancer therapy. The clinical-stage candidates in BCYC’s pipeline include BT1718, targeting MT1-MMP, and BT7480, a Nectin-4/CD137 TICA that is currently at the IND-enabling stage. The potential of the Bicycle platform extends beyond oncology, with possible applications in other therapeutic areas.

Looking Ahead: Focus on Execution and Expansion

Moving forward, BCYC’s priorities include the successful execution of its ongoing clinical programs, particularly for BT8009 and BT5528. The company is also advancing its broader BRC (Bicycle-based Radiopharmaceuticals) portfolio and next-generation programs. Updates are expected for BT8009 in additional tumor types, as well as combination data with pembrolizumab (pembro) in 1L mUC, either later this year or in early 2025.

BCYC’s innovative approach continues to generate excitement within the scientific and medical communities, with experts like Dr. Charles Swanton, a member of BCYC’s Scientific and Clinical Advisory Boards, expressing optimism about the platform’s potential beyond bladder cancer, particularly in non-small cell lung cancer (NSCLC).

With its novel therapeutic approach, favorable clinical data, and ongoing advancements, BCYC is well-positioned to make a meaningful impact on cancer treatment, providing hope for patients and fueling the company’s growth in the oncology space.

You might like this article:Intel Secures $3.5 Billion Federal Deal to Boost U.S. Military Chip Production

Tags: GrowthMoversNewsStock Market
Previous Post

Intel Secures $3.5 Billion Federal Deal to Boost U.S. Military Chip Production

Next Post

Hewlett Packard Enterprise Upgraded by Bank of America Amid Strategic Shift and Juniper Networks Acquisition

Related Posts

chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

byLiliana Vida
November 17, 2026
0

Pivotal REGAL trial demonstrates significant survival benefits, positioning the company for a potential FDA submission in 2027. SELLAS Life Sciences...

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

byLiliana Vida
November 11, 2026
0

Quantum computing company reports $4.5 million in revenue, strong year-to-date bookings, and potential access to $100 million in federal funding....

investing

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

byLuca Blaumann
November 10, 2026
0

Quantum computing company beats earnings expectations, reports $503 million in liquidity, and advances major technology initiatives across global markets. D-Wave...

Next Post
code-2

Hewlett Packard Enterprise Upgraded by Bank of America Amid Strategic Shift and Juniper Networks Acquisition

Latest News

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

Based on Your Interest

Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026
Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026

Recommended

Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Aerospace & Defense

SpaceX Secures Reported $45 Billion AI Infrastructure Deal With Anthropic

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%
  • CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
semiconductor-6

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

November 12, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.